Effectiveness of engineering the nontypeable Haemophilus influenzae antigen Omp26 as an S-layer fusion in bacterial ghosts as a mucosal vaccine delivery

Human Vaccines

Volumn 7, Issue SUPPL., 2011, Pages 99-107

  Riedmann, Eva M ^a   Lubitz, Werner ^a   McGrath, John ^b   Kyd, Jennelle M ^b   Cripps, Allan W ^c  

^a BIRD C GmbH and CoKG   (Austria)

^b CENTRAL QUEENSLAND UNIVERSITY   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

Author keywords

Bacterial ghosts; Mucosal immunization; NTHi; Omp26

Indexed keywords

BACTERIAL ANTIGEN; HAEMOPHILUS INFLUENZAE VACCINE; IMMUNOGLOBULIN G; OMP26 ANTIGEN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL MEMBRANE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HAEMOPHILUS INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RESISTANCE; LUNG CLEARANCE; MALE; MUCOSAL IMMUNITY; NONHUMAN; RAT; TH1 CELL;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; DRUG CARRIERS; ESCHERICHIA COLI; HAEMOPHILUS VACCINES; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; LYMPHOCYTES; MALE; MEMBRANE GLYCOPROTEINS; RATS; TH1 CELLS; VACCINATION; VACCINES, SYNTHETIC;

EID: 83155175385     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.0.14569     Document Type: Article

References (34)

1. Szostak MP, Lubitz W. Recombinant bacterial ghosts as multivaccine vehicles. In: Chanock RM, Ed. Modern approaches to new vaccines including prevention of AIDS Vaccines 91 New York, Cold Spring Harbor Laboratory Press 1991; 409-14.
2. Lubitz W. Bacterial ghosts as carrier and targeting systems. Expert Opin Biol Ther 2001; 1:765-71. (Pubitemid 33769736)
3. Lubitz W, Witte A, Eko FO, Kamal M, Jechlinger W, Brand E. Extended recombinant bacterial ghost system. J Biotechnol 1999; 73:261-73. (Pubitemid 29376457)
4. Katinger A, Lubitz W, Szostak MP, Stadler M, Klein R, Indra A. Pigs aerogenously immunized with genetically inactivated (ghosts) or irradiated Actinobacillus pleuropneumoniae are protected against a homologous aerosol challenge despite differing in pulmonary and antibody responses. J Biotechnol 1999; 73:251-60. (Pubitemid 29376456)
5. Huter V, Hensel A, Brand E, Lubitz W. Improved protection against lung colonization by Actinobacillus pleuropneumoniae ghosts: characterization of a genetically inactivated vaccine. J Biotechnol 2000; 83:161-72.
6. Szostak MP, Hensel A, Eko FO, Klein R, Auer T, Mader H. Bacterial ghosts: non living candidate vaccines. J Biotechnol 1996; 44:161-70. (Pubitemid 26059097)
7. Panthel K, Jechlinger W, Matis A, Rodhe M, Szostak MP, Lubitz W. Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates. Infect Immun 2003; 71:109-16. (Pubitemid 36026010)
8. Eko FO, Lubitz W, McMillan L, Ramey K, Moore TT, Ananaba GA. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine 2003; 21:1694-703. (Pubitemid 36292160)
9. Jechlinger W, Haidinger W, Paukner S, Mayrhofer P, Riedmann E, Marchart J. Bacterial ghosts as carrier and targeting systems for antigen delivery. In: Goebel GAaW, Ed. Vaccine Delivery Strategies. Wymondham: Horizon Scientific Press 2002; 163-84.
10. Mayr UB, Haller C, Haidinger W, Atrasheuskaya A, Bukin E, Lubitz W. Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge. Infect Immun 2005; 73:4810-7. (Pubitemid 41105637)
11. Smith RH, Messner P, Lamontage LR, Sleytr UB, Unger FM. Induction of T-cell immunity to oligosaccharide antigens immobilized on cyrstalline bacterial surface layers (S-layers). Vaccine 1993; 11:919-24. (Pubitemid 23218798)
12. Messner P, Unger FM, Sleytr UB. Vaccine Development based on S-layer technology. In: Sleytr UB, Messner P, Pum D, Sara M, Eds. Crystalline Bacterial Cell surface Proteins. Austin: R.G. Landes Company 1996; 161-73.
13. Messner P, Mazid MA, Unger FM, Sleytr UB. Artificial antigens. Synthetic carbohydrate haptens immobilized on crystalline bacterial surface layer glycoproteins. Carbohydr Res 1992; 233:175-84.
14. Jahn-Schmid B, Messner P, Unger FM, Sleytr UB, Scheiner O, Kraft D. Toward selective elictation of TH1-controlled vaccination responses: vaccine applications bacterial surface layer proteins. J Biotechnol 1996; 44:225-31.
15. Foxwell AR, Kyd JM, Cripps AW. Nontypeable Haemophilus influenzae: pathogenesis and prevention. Microbiol Mol Biol Rev 1998; 62:294-308. (Pubitemid 28270276)
16. St. Geme JW, III. The pathogenesis of nontypeable Haemophilus influenzae otitis media. Vaccine 2001; 19:41-50.
17. Bolduc GR, Bouchet V, Jiang RZ, Geisselsoder J, Truong-Bolduc QC, Rice PA. Variability of outer membrane protein P1 and its evaluation as a vaccine candidate against experimental otitis media due to nontypeable Haemophilus influenzae: an unambiguous multifaceted approach. Infect Immun 2000; 68:4505-17. (Pubitemid 30497717)
18. Kyd JM, Cripps AW. Modulation of antigen-specific T and B cell responses influence bacterial clearance of nontypeable Haemophilus influenzae from the lung in a rat model. Vaccine 1996; 14:1471-8. (Pubitemid 27008264)
19. Kyd JM, Dunkley ML, Cripps AW. Enhanced respiratory clearance of nontypeable Haemophilus influenzae following mucosal immunization with P6 in a rat model. Infect Immun 1995; 63:2931-40.
20. Kyd JM, Cripps AW. Potential of a novel protein, OMP26, from nontypeable Haemophilus influenzae to enhance pulmonary clearance in a rat model. Infect Immun 1998; 66:2272-8. (Pubitemid 28194130)
21. El-Adhami W, Kyd JM, Bastin DA, Cripps AW. Characterisation of the gene encoding a 26 kilodalton protein (OMP26) from nontypeable Haemophilus influenzae and immune responses to the recombinant protein. Infect Immun 1999; 67:1935-42. (Pubitemid 29144418)
22. Poolman JT, Bakaletz L, Cripps A, Danoël P, Forsgren A, Kyd J. Developing a nontypeable Haemophilus influenzae (NTHi) vaccine. Vaccine 2000; 19:108-15.
23. Kyd JM, Cripps AW, Novotny LA, Bakaletz LO. Efficacy of the 26 kilodalton outer membrane protein and two P5 fimbrin-derived immunogens to induce clearance of nontypeable Haemophilus influenzae from the rat middle ear and lungs as well as from the chinchilla middle ear and nasopharynx. Infect Immun 2003; 71:4691-9. (Pubitemid 36919937)
24. Riedmann EM, Kyd JM, Smith AM, Gomez-Gallego S, Jalava K, Cripps AW. Construction of recombinant S-layer proteins (rSbsA) and their expression in bacterial ghosts-a delivery system for the nontypeable Haemophilus influenzae antigen Omp26. FEMS Immunol Med Microbiol 2003; 37:185-92. (Pubitemid 36776502)
25. Kloos DU, Stratz M, Guttler A, Steffan RJ, Timmis KN. Inducible cell lysis system for the study of natural transformation and environmental fate of DNA released by cell death. J Bacteriol 1994; 176:7352-61. (Pubitemid 24364063)
26. Wallace FJ, Clancy RL, Cripps AW. An animal model demonstration of enhanced clearance of nontypeable Haemophilus influenzae from the respiratory tract after antigen stimulation of the gut-associated lymphoid tissue. Am Rev Respir Dis 1989; 140:311-6. (Pubitemid 19218341)
27. O'Hagan DT. Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Del Rev 1998; 34:305-20. (Pubitemid 28535117)
28. Challacombe SJ, Rahman D, O'Hagan DT. Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. Vaccine 1997; 15:169-75. (Pubitemid 27091247)
29. O'Hagan DT, MacKichan ML, Manmohan S. Recent development on adjuvants for vaccines against infectious diseases. Biomol Eng 2001; 18:69-85. (Pubitemid 32889607)
30. Jalava K, Eko FO, Riedmann E, Lubitz W. Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert Rev Vaccines 2003; 2:45-51. (Pubitemid 36559938)
31. Webb DC, Cripps AW. A method for the purification and refolding of a recombinant form of the nontypeable Haemophilus influenzae P5 outer membrane protein fused to polyhistidine. Protein Expr Purif 1999;15:1-7. (Pubitemid 29321462)
32. Cripps AW, Kyd JM. A vaccine for nontypable Haemophilus influenzae. In: Ellis R, Brodeur B, Eds. New Bacterial Vaccines. New York: Kluwer Academic/Plenum Publishers 2003; 244-59.
33. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 2001; 14:430-45. (Pubitemid 32294678)
34. Freihorst CE, Merick JM, Ogra PL. Effect of oral immunization with Pseudomonal aeruginosa on the development of specific antibacterial immunity in the lungs. Infect Immun 1989; 57:235-8.